Ortin Laboratories Ltd (BSE: 539287) is a Hyderabad, Telangana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹11 Cr, it ranks #4,742 by market cap among the 6,197 Indian listed companies on FinBizNet, and #79 of 86 in Medicinal Chemicals and Botanical Products. At ₹12.75 (as of 16 Nov 2026), the share price is 40.1% below its 52-week high of ₹21.30 and 15.9% above its 52-week low of ₹11.00. The share price is up 11.3% over one year and down 19.2% over three months.
| Current Price | ₹12.75 |
|---|---|
| Market Cap | ₹11 Cr |
| BSE Code | 539287 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | -45.96% |
| Return on Assets | -15.24% |
| 52-Week Range | ₹11.00 – ₹21.30 |
| 1-Year Price Change | +11.3% |
| 3-Month Price Change | -19.2% |
| Beta (1Y) | -0.13 |
| Dividend Yield | 0.00% |
| Headquarters | Hyderabad, Telangana |
| Website | www.ortinlabsindia.com |
| Revenue | ₹0 Cr |
|---|---|
| Net Profit | ₹-0 Cr |
| Net Margin | -900.0% |
| EPS (Basic) | ₹-0.33 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Ortin Laboratories Ltd reported revenue of ₹0 Cr in Q2 FY27, up 200.0% from ₹0 Cr in Q2 FY26 and up 200.0% from ₹0 Cr in Q1 FY27. It posted a net loss of ₹0 Cr for the quarter, against a net loss of ₹1 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹0 Cr (Q1 FY27) to ₹0 Cr (Q4 FY25). The company reported a net loss in 7 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹0 Cr | −₹0 Cr | −900.0% |
| Q1 FY27 | ₹0 Cr | −₹0 Cr | −3400.0% |
| Q4 FY26 | ₹0 Cr | −₹0 Cr | −33.3% |
| Q3 FY26 | ₹0 Cr | −₹0 Cr | −500.0% |
| Q2 FY26 | ₹0 Cr | −₹1 Cr | −5000.0% |
| Q1 FY26 | ₹0 Cr | −₹0 Cr | −450.0% |
| Q4 FY25 | ₹0 Cr | −₹0 Cr | −320.0% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 1.24% of Ortin Laboratories Ltd's shares as of Sept 2026, against 1.23% in Sept 2025 (+0.01 percentage points). Delivery averaged 79.2% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Ortin Global Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders; formulations, such as anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-pencillins, antifungal, cephalosporins, and macrolides. Its formulations also include chemo therapeutics, antacids and anti-ulcerants, anti-spasmodics, calcium and iron preparations, anti-arthritic drugs, protein supplements, enzymes, and vitamins, as well as psychiatry, appetizer, gynaec, and anti-retroviral products. In addition, the company offers active pharmaceutical ingredient (API) intermediates, including anti-retroviral, anti-diabetics, analgesics and antipyretics, anti-biotics, antifungal, antacids and anti-ulcerants, and anti-malarials; and manufactures fine chemi
1. Manufacturing of Pharmaceutical Products-This segment engages in the manufacture and sale of drug intermediates and pharmaceutical products.
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Ortin Laboratories Ltd | ₹11 Cr | n/m | -45.96% | ₹0 Cr | +11.3% |
Listed by market capitalisation. Ratios are shown for context only.
Ortin Laboratories Ltd is trading at ₹12.75, with a market capitalisation of ₹11 Cr.
Ortin Laboratories Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Ortin Laboratories Ltd has a return on equity of -45.96%.
Ortin Laboratories Ltd is listed on the BSE under the scrip code 539287.
Ortin Laboratories Ltd's share price is up 11.3% over one year and down 19.2% over three months. Its 52-week range is ₹11.00 to ₹21.30.
In Q2 FY27, Ortin Laboratories Ltd reported revenue of ₹0 Cr and net profit of ₹-0 Cr, with basic EPS of ₹-0.33 (standalone, parsed from the company's exchange filing).
Ortin Laboratories Ltd reported revenue of ₹0 Cr in Q2 FY27, up 200.0% from ₹0 Cr in Q2 FY26 and up 200.0% from ₹0 Cr in Q1 FY27.
Promoters held 1.24% of Ortin Laboratories Ltd's shares as of Sept 2026, against 1.23% in Sept 2025 (+0.01 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.